<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484872</url>
  </required_header>
  <id_info>
    <org_study_id>ELCWP01501</org_study_id>
    <nct_id>NCT02484872</nct_id>
  </id_info>
  <brief_title>Has Inflammation a Significant Implication in Lung Cancer Evolution?</brief_title>
  <official_title>L'Inflammation A-t-elle Une Implication Significative Dans l'Ã©volution du Cancer Bronchique?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the&#xD;
      Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of&#xD;
      the study is to look at the prognostic and predictive value of inflammation during cancer&#xD;
      evolution, on the risk of complications leading to ICU admission and the risk of death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood&#xD;
      sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and&#xD;
      in case of complication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Measured from diagnosis until death or last date known to be alive, or at least 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications leading to emergency/ICU</measure>
    <time_frame>From inclusion until death, or a least 48 months</time_frame>
    <description>Recording any complication leading to consultation at the emergency department or admission into the intensive care unit</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Lung neoplasms</arm_group_label>
    <description>Lung neoplasms irrespective of stage and histology</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling (serum)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed untreated lung neoplasms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lung neoplasms irrespective of stage, histology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously treated lung neoplasms&#xD;
&#xD;
          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ&#xD;
             carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free&#xD;
             interval)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Pascale Meert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Glasgow score</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Emergency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

